Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in the Russian Federation: results of the A1 cohort of the ISABELLA study

20245 citationsJournal Articlegold Open Access

Authors

Igor Samoylenko

Yu.M. Kolontareva

E. V. Kogay

Natalia V. Zhukova · City Clinical Oncology Center

Igor Utyashev

M. Е. Ivannikov · State Healthcare Institution "Regional Clinical Oncological Dispensary"

К. V. Menshikov

Maksim V. Zinkevich · State Healthcare Institution "Regional Clinical Oncological Dispensary"

Kristina V. Orlova

Abstract

Triple combination of atezolizumab, vemurafenib, and cobimetinib had proven its efficacy and tolerability in real settings. No impact of potential predictive biomarkers was seen (NCT05402059).

Topics & Keywords

Melanoma and MAPK Pathways Cancer Immunotherapy and Biomarkers Cytokine Signaling Pathways and Interactions

Publication Details

Published in: Frontiers in Oncology

Volume 14, pp. 1395378-1395378

DOI: 10.3389/fonc.2024.1395378

Field-Weighted Citation Impact: 1.23

Command Palette

Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in the Russian Federation: results of the A1 cohort of the ISABELLA study

Authors

Abstract

Topics & Keywords

Publication Details